Cargando…
Nanomaterials for cancer therapy: current progress and perspectives
Cancer is a disease with complex pathological process. Current chemotherapy faces problems such as lack of specificity, cytotoxicity, induction of multi-drug resistance and stem-like cells growth. Nanomaterials are materials in the nanorange 1–100 nm which possess unique optical, magnetic, and elect...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165984/ https://www.ncbi.nlm.nih.gov/pubmed/34059100 http://dx.doi.org/10.1186/s13045-021-01096-0 |
_version_ | 1783701424019865600 |
---|---|
author | Cheng, Zhe Li, Maoyu Dey, Raja Chen, Yongheng |
author_facet | Cheng, Zhe Li, Maoyu Dey, Raja Chen, Yongheng |
author_sort | Cheng, Zhe |
collection | PubMed |
description | Cancer is a disease with complex pathological process. Current chemotherapy faces problems such as lack of specificity, cytotoxicity, induction of multi-drug resistance and stem-like cells growth. Nanomaterials are materials in the nanorange 1–100 nm which possess unique optical, magnetic, and electrical properties. Nanomaterials used in cancer therapy can be classified into several main categories. Targeting cancer cells, tumor microenvironment, and immune system, these nanomaterials have been modified for a wide range of cancer therapies to overcome toxicity and lack of specificity, enhance drug capacity as well as bioavailability. Although the number of studies has been increasing, the number of approved nano-drugs has not increased much over the years. To better improve clinical translation, further research is needed for targeted drug delivery by nano-carriers to reduce toxicity, enhance permeability and retention effects, and minimize the shielding effect of protein corona. This review summarizes novel nanomaterials fabricated in research and clinical use, discusses current limitations and obstacles that hinder the translation from research to clinical use, and provides suggestions for more efficient adoption of nanomaterials in cancer therapy. |
format | Online Article Text |
id | pubmed-8165984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81659842021-06-02 Nanomaterials for cancer therapy: current progress and perspectives Cheng, Zhe Li, Maoyu Dey, Raja Chen, Yongheng J Hematol Oncol Review Cancer is a disease with complex pathological process. Current chemotherapy faces problems such as lack of specificity, cytotoxicity, induction of multi-drug resistance and stem-like cells growth. Nanomaterials are materials in the nanorange 1–100 nm which possess unique optical, magnetic, and electrical properties. Nanomaterials used in cancer therapy can be classified into several main categories. Targeting cancer cells, tumor microenvironment, and immune system, these nanomaterials have been modified for a wide range of cancer therapies to overcome toxicity and lack of specificity, enhance drug capacity as well as bioavailability. Although the number of studies has been increasing, the number of approved nano-drugs has not increased much over the years. To better improve clinical translation, further research is needed for targeted drug delivery by nano-carriers to reduce toxicity, enhance permeability and retention effects, and minimize the shielding effect of protein corona. This review summarizes novel nanomaterials fabricated in research and clinical use, discusses current limitations and obstacles that hinder the translation from research to clinical use, and provides suggestions for more efficient adoption of nanomaterials in cancer therapy. BioMed Central 2021-05-31 /pmc/articles/PMC8165984/ /pubmed/34059100 http://dx.doi.org/10.1186/s13045-021-01096-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Cheng, Zhe Li, Maoyu Dey, Raja Chen, Yongheng Nanomaterials for cancer therapy: current progress and perspectives |
title | Nanomaterials for cancer therapy: current progress and perspectives |
title_full | Nanomaterials for cancer therapy: current progress and perspectives |
title_fullStr | Nanomaterials for cancer therapy: current progress and perspectives |
title_full_unstemmed | Nanomaterials for cancer therapy: current progress and perspectives |
title_short | Nanomaterials for cancer therapy: current progress and perspectives |
title_sort | nanomaterials for cancer therapy: current progress and perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165984/ https://www.ncbi.nlm.nih.gov/pubmed/34059100 http://dx.doi.org/10.1186/s13045-021-01096-0 |
work_keys_str_mv | AT chengzhe nanomaterialsforcancertherapycurrentprogressandperspectives AT limaoyu nanomaterialsforcancertherapycurrentprogressandperspectives AT deyraja nanomaterialsforcancertherapycurrentprogressandperspectives AT chenyongheng nanomaterialsforcancertherapycurrentprogressandperspectives |